A Proof-of-Concept Study for an Experimental Hurler Syndrome Treatment is Going Well so Far
sasint / Pixabay

A Proof-of-Concept Study for an Experimental Hurler Syndrome Treatment is Going Well so Far

According to a story from sectorpublishingintelligence.co.uk, the biopharmaceutical company Orchard Therapeutics recently announced the release of some data from an ongoing proof-of-concept study. This special trial is testing the company's…

Continue Reading A Proof-of-Concept Study for an Experimental Hurler Syndrome Treatment is Going Well so Far

CRISPR Gene Editing Promises to Cure 10,000 diseases. Now in Its First Human Clinical Trial. Will it Eventually Deliver?

  Clustered Regularly Interspaced Short Palindromic Repeats is more commonly known as CRISPR. As reported recently in Science News, the CRISPR/Cas9 “molecular scissors” is slated to make its highly anticipated debut…

Continue Reading CRISPR Gene Editing Promises to Cure 10,000 diseases. Now in Its First Human Clinical Trial. Will it Eventually Deliver?
FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug
mohamed_hassan / Pixabay

FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug

According to a press release from Maryland-based Viela Bio, the US Food and Drug Administration (FDA) recently agreed to review the Company's Biologics License Application for its neuromyelitis optica spectrum…

Continue Reading FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug

Biomedical Innovation Law Expert Presents Ethical Difficulties Posed by Gene Editing

According to a publication from Charcot Marie Tooth News, biomedical law expert Timo Minssen recently gave a presentation at the New York Genome Center where he discussed the potential ethical…

Continue Reading Biomedical Innovation Law Expert Presents Ethical Difficulties Posed by Gene Editing

The Power of Collective Action in Providing Insurance Coverage for Spinal Muscular Atrophy Gene Therapy

Maisie Green Maisie Green is a 20-month-old little girl whose insurance has finally approved coverage for a life-altering spinal muscular atrophy treatment. Two weeks ago she received the singular infusion…

Continue Reading The Power of Collective Action in Providing Insurance Coverage for Spinal Muscular Atrophy Gene Therapy
At Age 6, A Boy Finally Discovers His Disease: He’s The First To Be Diagnosed With It
PNH causes the immune system to destroy red blood cells. Source: pixabay.com

At Age 6, A Boy Finally Discovers His Disease: He’s The First To Be Diagnosed With It

Originally reported in People Magazine, a family struggled for years to figure out what was happening to their son, Cohen Bramlee, who for years received his nutrients from a central…

Continue Reading At Age 6, A Boy Finally Discovers His Disease: He’s The First To Be Diagnosed With It

UPDATE: Trump Admin Reconsiders Decision to Deport Migrants Receiving Life-Saving Treatment 

Last week, we spotlighted a New York Times story about how under the Trump Administration’s new immigration policy, six migrants undergoing lifesaving treatments would be abruptly deported; including a young woman…

Continue Reading UPDATE: Trump Admin Reconsiders Decision to Deport Migrants Receiving Life-Saving Treatment 
A Tale of Two Sisters With Cystic Fibrosis Highlights the Barriers to Treatment Access That Still Remain
Free-Photos / Pixabay

A Tale of Two Sisters With Cystic Fibrosis Highlights the Barriers to Treatment Access That Still Remain

According to a story from the Sunday Post, sisters Shona and Kirsty Young, aged 24 and 29 years respectively, were both born with the devastating rare disease cystic fibrosis. However,…

Continue Reading A Tale of Two Sisters With Cystic Fibrosis Highlights the Barriers to Treatment Access That Still Remain

Zogenix Acquires Modis in $400 Million Buyout, Adds Experimental TK2 mDNA Depletion Syndrome Treatment to Pipeline

According to a press release from California-based biotechnology company Zogenix, the Company recently completed a multi-million dollar acquisition of Modis Therapeutics. Before its acquisition, Modis focused on the development of…

Continue Reading Zogenix Acquires Modis in $400 Million Buyout, Adds Experimental TK2 mDNA Depletion Syndrome Treatment to Pipeline